期刊
CANCER AND METASTASIS REVIEWS
卷 39, 期 2, 页码 519-534出版社
SPRINGER
DOI: 10.1007/s10555-020-09870-1
关键词
Sodium-hydrogen exchanger; NHE6; NHE9; RACK1; Breast cancer; Glioblastoma; Chemoresistance; And protons
类别
资金
- Ruth L. Kirschstein Individual National Research Service Award [F31CA220967]
- NIH [R01DK108304]
- BSF [13044]
- Mayo Clinic Professorship
- Mayo Clinic Clinician Investigator award
- Florida Department of Health Cancer Research Chair Fund
- National Institutes of Health [R43CA221490, R01CA200399, R01CA195503, R01CA216855]
Extracellular acidification is a well-known driver of tumorigenesis that has been extensively studied. In contrast, the role of endosomal pH is novel and relatively unexplored. There is emerging evidence from a growing number of studies showing that the pH of endosomal compartments controls proliferation, migration, stemness, and sensitivity to chemoradiation therapy in a variety of tumors. Endosomes are a crucial hub, mediating cellular communication with the external environment. By finely regulating the sorting and trafficking of vesicular cargo for degradation or recycling, endosomal pH determines the fate of plasma membrane proteins, lipids, and extracellular signals including growth factor receptors and their ligands. Several critical regulators of endosomal pH have been identified, including multiple isoforms of the family of electroneutral Na+/H+ exchangers (NHE) such as NHE6 and NHE9. Recent studies have shed light on molecular mechanisms linking endosomal pH to cancer malignancy. Manipulating endosomal pH by epigenetic reprogramming, small molecules, or nanoparticles may offer promising new options in cancer therapy. In this review, we summarize evidence linking endosomal pH to cancer, with a focus on the role of endosomal Na+/H+ exchangers and how they affect the prognosis of cancer patients, and also suggest how regulation of endosomal pH may be exploited to develop new cancer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据